Obesity rates are rising, despite GLP-1s. What does it mean?
By 2030, nearly half of all American adults will have obesity, according to research published in the New England Journal of Medicine. In every single state, researchers expect at least 35% of adults to have a body mass index of 30 or higher, the threshold that defines obesity. That prediction may come as a shock, as weight loss medications like Wegovy and Zepbound become more popular and more affordable.
Combining GLP-1 drugs with hormones may lower uterine cancer risk
Adding GLP-1 medications like Ozempic to progestin therapy could cut the risk of developing endometrial cancer. A retrospective study published in the journal JAMA Network Open found that women using this combination had a much lower risk of developing the disease than those on progestins alone.
Lilly appeals retatrutide classification ruling in case that could impact compounders
Eli Lilly is challenging a decision over how the FDA classified its experimental, next-gen obesity shot, in a case that could affect the ability of compounders to rival it.
On Thursday, Lilly filed a notice …
FDA Leader Accused of Sexual Harassment; RFK Jr.’s Toilet Comment; GLP-1s and Scurvy
(MedPage Today) — Note that some links may require registration or subscription.
FDA vaccine chief Vinay Prasad, MD, MPH, who made the controversial decision to refuse to review Moderna’s mRNA flu vaccine, has been accused of sexual harassment…
Lilly Prepares $1B+ Orforglipron Stock Ahead of Approval as Novo Brings Wegovy Pill Overseas
Eli Lilly has long been gearing up for the launch of orforglipron, announcing as early as February 2024 that it was ramping up manufacturing investments for the weight-loss pill.
STAT+: Trump administration is urged to use a federal law to authorize generic versions of GLP-1 drugs
Public Citizen contends that Novo Nordisk and Eli Lilly’s obesity drugs are straining budgets so much that generics should be authorized.
Potentially Blinding Eye Condition Tied to Ozempic Again
(MedPage Today) — Risk for a rare, potentially blinding eye condition was low, but it was significantly higher in diabetes patients who started semaglutide (Ozempic) versus SGLT2 inhibitors, an observational study of U.S. veterans showed.
Among…
Novo Nordisk to expand Irish factory for Wegovy pill
Novo Nordisk is ramping up its footprint in Ireland with a planned expansion of its Athlone factory to make its Wegovy pill, the company confirmed to Endpoints News.
The Athlone site will supply the pill …
Viking to push oral GLP-1/GIP drug into phase III obesity trial
Viking Therapeutics Inc. said after-market hours Feb. 11 that it plans to advance its oral dual GLP-1/GIP receptor, VK-2735, into a phase III trial for obesity in the third quarter of 2026. VK-2735 is a novel dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor agonist.
How employers feel about the state of healthcare (and GLP-1s)
A few weeks back, I moderated a dinner conversation among company heads of HR and benefits here in Denver organized by primary care operator Marathon Health.
These employee benefit leaders are a group I hear …